Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21450719 | 0.81 | HTT (0.39) | ABL1RETKDRCDK7CDK5 | |
| SCHEMBL988470 | 0.81 | L3MBTL1 (0.37) | ABL1RETKDRCDK7CDK5 | |
| SCHEMBL15746243 | 0.78 | ALDH1A1 (0.33) | ABL1RETKDRCDK7CDK5 | |
| SCHEMBL14336652 | 0.78 | POLB (0.40) | L3MBTL1ALDH1A1SMN1; SMN2CYP1A2KCNH2 | |
| SCHEMBL7916579 | 0.77 | CDK5 (0.42) | ABL1RETKDRCDK7CDK5 | |
| SCHEMBL12724907 | 0.76 | ABL1 (0.37) | ABL1RETKDRCDK7CDK5 | |
| SCHEMBL984674 | 0.74 | ALDH1A1 (0.56) | ABL1KDRCDK7CDK5AURKB | |
| SCHEMBL8239704 | 0.74 | FABP6 (0.44) | ABL1RETKDRCDK7CDK5 | |
| SCHEMBL15177588 | 0.73 | PDK2 (0.36) | L3MBTL1ALDH1A1SMN1; SMN2PDK2PDK4 | |
| SCHEMBL5021592 | 0.73 | L3MBTL1 (0.35) | L3MBTL1ALDH1A1SMN1; SMN2KCNH2SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-7932257-B2 | Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | AURKA, AURKB, AURKC | ABL1 66/4885RET 898/4885KDR 1997/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | ABL1 193/4885RET 1415/4885KDR 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.